Loading patent…
Assigneeargenx BVBA
InventorsChristophe BLANCHETOT, Marie GODAR, Bart LAMBRECHT
Estimating the term…
The present invention relates to combination therapies and to their use in the treatment of chronic airway disease, particularly use in the treatment of asthma. The combination therapies comprise (i) an antagonist of IL-5:IL-5R and (ii) an antagonist of IL-4:IL-4R and/or an antagonist of IL-13:IL-13R. The present invention also provides bispecific antibodies comprising an antigen binding domain that binds to IL-4Rα and an antigen binding domain that binds to IL-5. The bispecific antibodies may be used for the treatment of chronic airway disease, particularly asthma.
A combination comprising:
The combination of any one of the preceding claims, wherein the combination comprises one or more additional therapeutic agents.
A bispecific antibody comprising an antigen binding region that binds to IL-4Rα and an antigen binding region that binds to IL-5.
An antagonist of IL-5:IL-5R for use in the treatment of chronic airway disease in a human subject, wherein the antagonist is administered in combination with an antagonist of IL-4:IL-4R and/or an antagonist of IL-13:IL-13R.
An antagonist of IL-4:IL-4R and/or an antagonist of IL-13:IL-13R for use in the treatment of chronic airway disease in a human subject, wherein the antagonist is administered in combination with an antagonist of IL-5:IL-5R.
Dependencies are inferred from the claim text.